Blake Insomnia Therapeutics has a patent pending compound, branded as Zleepax, that uses a beta blocker called Nebivolol as its primary ingredient, and the ingredient that helps to induce sleep, reports Equities.

Both Belsomra and E-2006, as well as a previous global bestseller, Lunesta, induce the residual daytime tiredness that Blake Insomnia Therapeutics is trying to overcome with Zleepax. The path to approval for these types of drugs is relatively long, but if Zleepax can successfully navigate through to regulatory approval in the US, and if it can pick up a label that states it removes the potential for residual tiredness, it could quickly start to eat away at the market share of the current leaders.